BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $128,026,872 | -4.3% | 1,880,812 | +14.8% | 0.03% | -2.9% |
| Q2 2023 | $133,794,918 | -11.0% | 1,639,041 | -19.1% | 0.04% | -16.7% |
| Q1 2023 | $150,351,449 | -1.5% | 2,026,573 | +10.1% | 0.04% | -6.7% |
| Q4 2022 | $152,620,952 | +22.4% | 1,841,469 | +319.5% | 0.04% | +12.5% |
| Q3 2022 | $124,677,000 | -26.6% | 439,003 | -10.4% | 0.04% | -21.6% |
| Q2 2022 | $169,852,000 | -18.3% | 489,994 | +2.1% | 0.05% | -3.8% |
| Q1 2022 | $207,830,000 | -18.0% | 479,936 | -2.0% | 0.05% | -13.1% |
| Q4 2021 | $253,447,000 | +15.5% | 489,904 | +8.2% | 0.06% | +8.9% |
| Q3 2021 | $219,391,000 | -15.2% | 452,754 | -21.2% | 0.06% | -12.5% |
| Q2 2021 | $258,645,000 | -10.7% | 574,436 | -24.2% | 0.06% | -16.9% |
| Q1 2021 | $289,478,000 | +24.3% | 757,933 | +3.4% | 0.08% | +13.2% |
| Q4 2020 | $232,831,000 | +32.4% | 733,208 | +3.3% | 0.07% | +15.3% |
| Q3 2020 | $175,894,000 | -22.7% | 710,022 | -17.6% | 0.06% | -27.2% |
| Q2 2020 | $227,406,000 | +77.1% | 861,161 | +27.1% | 0.08% | +50.0% |
| Q1 2020 | $128,428,000 | -43.6% | 677,292 | -34.7% | 0.05% | -23.9% |
| Q4 2019 | $227,765,000 | +14.5% | 1,037,606 | +2.1% | 0.07% | +36.5% |
| Q3 2019 | $198,867,000 | -10.4% | 1,016,339 | -4.5% | 0.05% | -8.8% |
| Q2 2019 | $221,874,000 | +106.9% | 1,064,196 | +97.1% | 0.06% | +58.3% |
| Q1 2019 | $107,213,000 | +33.8% | 539,980 | -2.5% | 0.04% | +16.1% |
| Q4 2018 | $80,132,000 | -42.2% | 553,702 | -18.5% | 0.03% | -29.5% |
| Q3 2018 | $138,676,000 | +34.0% | 679,421 | -2.9% | 0.04% | +29.4% |
| Q2 2018 | $103,482,000 | +1.9% | 699,439 | +4.1% | 0.03% | -10.5% |
| Q1 2018 | $101,519,000 | +13.2% | 672,135 | -2.9% | 0.04% | +18.8% |
| Q4 2017 | $89,677,000 | -0.5% | 692,216 | -7.2% | 0.03% | -3.0% |
| Q3 2017 | $90,137,000 | +20.5% | 745,614 | +17.1% | 0.03% | +43.5% |
| Q2 2017 | $74,790,000 | +25.0% | 636,507 | +8.1% | 0.02% | +15.0% |
| Q1 2017 | $59,844,000 | -32.5% | 588,724 | -31.7% | 0.02% | -33.3% |
| Q4 2016 | $88,693,000 | -6.3% | 862,527 | -0.3% | 0.03% | -9.1% |
| Q3 2016 | $94,703,000 | -10.1% | 864,864 | -7.4% | 0.03% | -15.4% |
| Q2 2016 | $105,369,000 | +19.0% | 934,388 | -0.2% | 0.04% | +8.3% |
| Q1 2016 | $88,537,000 | +3.9% | 936,709 | -1.1% | 0.04% | +5.9% |
| Q4 2015 | $85,240,000 | -2.6% | 947,118 | +0.0% | 0.03% | -8.1% |
| Q3 2015 | $87,555,000 | -6.1% | 946,945 | +0.0% | 0.04% | 0.0% |
| Q2 2015 | $93,204,000 | -1.3% | 946,530 | +0.5% | 0.04% | 0.0% |
| Q1 2015 | $94,444,000 | -6.3% | 941,704 | -13.7% | 0.04% | -5.1% |
| Q4 2014 | $100,838,000 | – | 1,091,325 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |